Cadonilimab Combined With Anlotinib in Locally Advanced or Relapsed/Metastatic Esophageal Squamous Cell Carcinoma Patients After Failure of PD-1 Inhibitor Combined With Platinum-containing Chemotherapy: A Single-center, Single-arm Exploratory Study
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Cadonilimab (Primary) ; Catequentinib (Primary)
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 07 Sep 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Aug 2023 to 1 Sep 2023.
- 18 Aug 2023 New trial record